Bernstein upgraded Agilon Health (AGL) to Outperform from Market Perform with an $8.50 price target The upgrade reflects improved confidence in the company’s turnaround plan and cash position, the analyst tells investors in a research note. The firm says it has received several data points that increase its confidence in Agilon’s turnaround plan, thus lowering risk of a capital rise. The company has shown solid progress in its multi-pronged turnaround, contends Bernstein.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health: Hold Rating Amid Uncertainty and Strategic Improvements
- Agilon Health: Strategic Focus and Conservative Guidance Drive Buy Rating Amidst Modest Q4 Improvement
- Agilon Health Faces Financial Challenges Amid Rising Costs and Enrollment Risks: Analyst Recommends Sell Rating
- Agilon Health’s Earnings Call: Growth Amid Challenges
- Agilon Health price target raised to $4 from $3 at Benchmark